A case report highlights the use of rituximab as a steroid-sparing therapy in pediatric patients with idiopathic pulmonary hemosiderosis. This approach may offer a new treatment strategy for managing this rare condition.
rituximab as a steroid sparing therapy in pediatric idiopathic pulmonary hemosiderosis a case report
Original title: “Rituximab as a Steroid-Sparing Therapy in Pediatric Idiopathic Pulmonary Hemosiderosis: A Case Report.”